期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 105, 期 2, 页码 363-375出版社
WILEY
DOI: 10.1002/cpt.1017
关键词
-
资金
- Bristol-Myers Squibb (BMS)
Cancer is a growing public health problem in China. Despite the high unmet medical need of patients with cancer in China, oncology drug approvals have historically lagged behind those in the West, mainly the United States and Europe. China is currently undertaking regulatory reforms at a fast pace in order to mitigate this lag.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据